These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15077652)

  • 1. Drug development in spinal cord injury: what is the FDA looking for?
    Hall ED
    J Rehabil Res Dev; 2003; 40(4 Suppl 1):81-91. PubMed ID: 15077652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection and acute spinal cord injury: a reappraisal.
    Hall ED; Springer JE
    NeuroRx; 2004 Jan; 1(1):80-100. PubMed ID: 15717009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of acute spinal cord injury: how do we build on past success?
    Hall ED
    J Spinal Cord Med; 2001; 24(3):142-6. PubMed ID: 11585231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of postinjury treatment with methylprednisolone or tirilazad mesylate on the increase in eicosanoid levels in the acutely injured cat spinal cord.
    Hall ED; Yonkers PA; Taylor BM; Sun FF
    J Neurotrauma; 1995 Jun; 12(3):245-56. PubMed ID: 7473799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury.
    Hall ED
    Cell Mol Neurobiol; 1993 Aug; 13(4):415-32. PubMed ID: 8252611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
    Bracken MB; Shepard MJ; Holford TR; Leo-Summers L; Aldrich EF; Fazl M; Fehlings M; Herr DL; Hitchon PW; Marshall LF; Nockels RP; Pascale V; Perot PL; Piepmeier J; Sonntag VK; Wagner F; Wilberger JE; Winn HR; Young W
    JAMA; 1997 May; 277(20):1597-604. PubMed ID: 9168289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant therapies for acute spinal cord injury.
    Hall ED
    Neurotherapeutics; 2011 Apr; 8(2):152-67. PubMed ID: 21424941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III.
    Bracken MB; Holford TR
    J Neurosurg; 2002 Apr; 96(3 Suppl):259-66. PubMed ID: 11990832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial.
    Bracken MB; Shepard MJ; Holford TR; Leo-Summers L; Aldrich EF; Fazl M; Fehlings MG; Herr DL; Hitchon PW; Marshall LF; Nockels RP; Pascale V; Perot PL; Piepmeier J; Sonntag VK; Wagner F; Wilberger JE; Winn HR; Young W
    J Neurosurg; 1998 Nov; 89(5):699-706. PubMed ID: 9817404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury.
    Hall ED; Yonkers PA; Andrus PK; Cox JW; Anderson DK
    J Neurotrauma; 1992 May; 9 Suppl 2():S425-42. PubMed ID: 1613805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury.
    Cayli SR; Kocak A; Yilmaz U; Tekiner A; Erbil M; Ozturk C; Batcioglu K; Yologlu S
    Eur Spine J; 2004 Dec; 13(8):724-32. PubMed ID: 15232723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising pharmacological agents in the management of acute spinal cord injury.
    Seidl EC
    Crit Care Nurs Q; 1999 Aug; 22(2):44-50. PubMed ID: 10646442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mn (III) tetrakis (4-benzoic acid) porphyrin scavenges reactive species, reduces oxidative stress, and improves functional recovery after experimental spinal cord injury in rats: comparison with methylprednisolone.
    Liu D; Shan Y; Valluru L; Bao F
    BMC Neurosci; 2013 Mar; 14():23. PubMed ID: 23452429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising pharmacological agents in the management of acute spinal cord injury.
    Seidl EC
    Pharm Pract Manag Q; 2000 Apr; 20(1):21-7. PubMed ID: 10947539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of glucocorticoid and nonglucocorticoid steroids on acute neuronal degeneration.
    Hall ED
    Adv Neurol; 1993; 59():241-8. PubMed ID: 8420108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury.
    Kaptanoglu E; Tuncel M; Palaoglu S; Konan A; Demirpençe E; Kilinç K
    J Neurosurg; 2000 Jul; 93(1 Suppl):77-84. PubMed ID: 10879762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for improving injury outcome in spinal cord injuries.
    Werner PC
    West J Med; 1997 Apr; 166(4):271-2. PubMed ID: 9168687
    [No Abstract]   [Full Text] [Related]  

  • 18. New pharmacological treatment of acute spinal cord trauma.
    Hall ED; Braughler JM; McCall JM
    J Neurotrauma; 1988; 5(1):81-9. PubMed ID: 3057217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of lipid peroxidation after acute spinal cord injury in rats and the effect of methylprednisolone.
    Christie SD; Comeau B; Myers T; Sadi D; Purdy M; Mendez I
    Neurosurg Focus; 2008; 25(5):E5. PubMed ID: 18980479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of deferoxamine and methylprednisolone: protective effect of pharmacological agents on lipid peroxidation in spinal cord injury in rats.
    Dinc C; Iplikcioglu AC; Atabey C; Eroglu A; Topuz K; Ipcioglu O; Demirel D
    Spine (Phila Pa 1976); 2013 Dec; 38(26):E1649-55. PubMed ID: 24108296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.